Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
Fiche publication
Date publication
août 2021
Journal
Cancer medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Pobel C, Auclin E, Teyssonneau D, Laguerre B, Cancel M, Boughalem E, Noel J, Brachet PE, Maillet D, Barthelemy P, Helissey C, Thibault C, Oudard S
Lien Pubmed
Résumé
Cabazitaxel multiple rechallenges may be a treatment option in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who had a good initial response to cabazitaxel and who are still fit to receive it. Our objective was to assess the efficacy and toxicity of multiple rechallenges.
Mots clés
cancer management, chemotherapy, metastasis, prostate cancer, urological oncology
Référence
Cancer Med. 2021 Aug 12;: